Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $48.35 (market cap $561.25M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 22.4× First Trust NASDAQ Clean Edge Green Energy Idx Fd's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and First Trust NASDAQ Clean Edge Green Energy Idx Fd for 50 Days on average.
| HALO | QCLN | |
|---|---|---|
Market Cap | $12.58B | $561.25M |
Volume | 2,179,278 | 323,550 |
Sector | Health | Sector/Thematic |
52-Week High | $115.22 | $68.47 |
52-Week Low | $61.63 | $41.10 |
Typical Hold Time | 1 Days | 50 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QCLN trades at $48.35, down 2.2% today, with technical indicators showing a bullish moving average signal but neutral oscillators. The ETF's performance is heavily influenced by U.S. clean energy policy and geopolitical developments, with recent news highlighting global renewable energy acceleration amid tensions. Support and resistance levels cluster around $50-$52, indicating a key price zone for near-term direction.
The outlook for QCLN hinges on political support for clean energy and rising electricity demand, offering growth potential but facing volatility from policy shifts. Risks include regulatory uncertainty and competitive pressures, while analyst sentiment remains watchful amid evolving market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
